Literature DB >> 11514644

Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease.

D Aarsland1, C Ballard, I McKeith, R H Perry, J P Larsen.   

Abstract

Extrapyramidal signs (EPS) were compared in 98 dementia with Lewy bodies (DLB) and 130 medication-responsive Parkinson's disease (PD) patients. DLB patients were older at assessment and at disease onset, were cognitively more impaired, and had a shorter duration of disease than PD patients. Sixty-seven DLB patients (68%) showed EPS. The 58 DLB patients with complete data had more severe action tremor, body bradykinesia, difficulty arising from a chair, and facial expression, gait, and rigidity symptoms than PD patients (all P<0.001). Abnormal posture and tremor at rest did not differ. Severity of EPS correlated with age, duration of disease, and cognitive impairment in PD patients but not in DLB patients. Studies of the clinical significance and management of EPS in DLB patients are needed.

Entities:  

Mesh:

Year:  2001        PMID: 11514644     DOI: 10.1176/jnp.13.3.374

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  20 in total

1.  Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Bradley F Boeve; Jonathan Graff-Radford; Walter A Rocca; Michelle M Mielke
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

Review 2.  Update on dementia with Lewy bodies.

Authors:  David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

3.  The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease.

Authors:  Micaela Mitolo; David P Salmon; Simona Gardini; Douglas Galasko; Enzo Grossi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 4.  Dementia with Lewy bodies. Review of diagnosis and pharmacologic management.

Authors:  Christopher Frank
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

Review 5.  Benefit-risk considerations in the treatment of dementia with Lewy bodies.

Authors:  Margaret M Swanberg; Jeffrey L Cummings
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.

Authors:  J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2009-10-07       Impact factor: 4.891

7.  Lewy body cortical involvement may not always predict dementia in Parkinson's disease.

Authors:  C Colosimo; A J Hughes; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

8.  Structural and functional imaging in parkinsonian syndromes.

Authors:  Stephen M Broski; Christopher H Hunt; Geoffrey B Johnson; Robert F Morreale; Val J Lowe; Patrick J Peller
Journal:  Radiographics       Date:  2014 Sep-Oct       Impact factor: 5.333

9.  Dementia with Lewy bodies.

Authors:  Ian McKeith
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

10.  Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.

Authors:  Moussa B H Youdim
Journal:  Exp Neurobiol       Date:  2013-03-31       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.